No alteration in the PFA-100 in vitro bleeding time induced by the Ginkgo biloba special extract, EGb 761, in elderly patients with mild cognitive impairment


Halil M. G. , CANKURTARAN M., YAVUZ B., OZKAYAR N., ULGER Z., DEDE D., ...Daha Fazla

BLOOD COAGULATION & FIBRINOLYSIS, cilt.16, ss.349-353, 2005 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 16 Konu: 5
  • Basım Tarihi: 2005
  • Doi Numarası: 10.1097/01.mbc.0000172695.62363.57
  • Dergi Adı: BLOOD COAGULATION & FIBRINOLYSIS
  • Sayfa Sayıları: ss.349-353

Özet

EGb 761 is widely used in the management of mild cognitive impairment in the elderly population. Elucidation of the effects of EGb 761 on primary haemostasis via PFA-100 could represent an important step for better understanding of the haemostatic safety of EGb 761. The purpose of this prospective study is to assess the effects of Ginkgo biloba special extract, EGb 761, on PFA-1 00 in vitro bleeding time in elderly patients with mild cognitive impairment. A total of 40 elderly patients aged 65 - 79 years who were referred for geriatric assessment and who were diagnosed as having mild cognitive impairment were included. Patients were started on 80 mg EGb-761 three times daily. The complete set of PFA-100 in vitro bleeding time and coagulation parameters including prothrombin time, activated partial thromboplastin time and International Normalized Ratio were assessed before and on the seventh day of treatment with EGb 761. There was no statistically significant prolongation in PFA-100 in vitro bleeding time or coagulation parameters in patients receiving EGb 761 after 7 days. The data about the safety of EGb 761 from the point of primary haemostasis in our elderly patient population with mild cognitive impairment casts hope for the future management of this 'difficult-to-treat' population with the promising Ginkgo extracts.